Abstracts Archive - Page 1149 of 2607 - ACR Meeting Abstracts

Abstract Number: 194 • 2019 ACR/ARP Annual Meeting
Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data
Fredrik Johansson¹, Jamie Collins ², Sara Gale ³, Hongshu Guan ⁴, Seoyoung C. Kim ⁵, Elena Losina ⁶, David Sontag ¹, Jacklyn Stratton ⁴, Huong Trinh ³, Jeffrey Greenberg ⁷ and Daniel Solomon ⁸, ¹MIT, Cambridge, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Genentech, San Francisco, CA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁸Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Predicting remission in rheumatoid arthritis (RA) is an important goal for tailoring therapy. Tocilizumab (TCZ) has been found in randomized controlled trials (RCT) to…
Abstract Number: 195 • 2019 ACR/ARP Annual Meeting
The Clinical Characteristics of Patients with Inflammatory Arthritis and a Persistently Low Alkaline Phosphatase Level in a Veteran Affairs Rheumatology Clinic
Luke Monteagudo¹, Amy Gravely ², Peter Valen ³ and David Ewart ³, ¹The University of Minnesota, Minneapolis, ²Minneapolis Veteran Affairs Medical Center, Minneapolis, ³University of Minnesota School of Medicine/ Minneapolis Veteran Affairs Medical Center, Minneapolis
Background/Purpose: Background: The biochemical hallmark of hypophosphatasia (HPP) is a low alkaline phosphatase (ALP) level. It is recognized that some forms of HPP present in adulthood…
Abstract Number: 196 • 2019 ACR/ARP Annual Meeting
Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro ², Rebecca Schumacher ², Teresa Simon ³ and Kaleb Michaud ¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb*, Princeton, NJ
Background/Purpose: With the advent of JAK inhibitors has come increased concerns for the risk of venous thromboembolism (VTE), which was already known to be increased…
Abstract Number: 197 • 2019 ACR/ARP Annual Meeting
The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application
Harriet Dickinson ¹, Yunhao Liu ² and Rachel Williams³, ¹GSK, Stevenage, United Kingdom, ²GSK, Upper providence, ³GSK, Upper Providence, PA
Background/Purpose: Pain is one of the most pressing problems for Rheumatoid Arthritis (RA) patients and contributes substantially towards fatigue and disability. Experiences of pain in…
Abstract Number: 198 • 2019 ACR/ARP Annual Meeting
Assessing Care Quality in Rheumatology Services
Mark Yates¹, Sam Norton ¹, Alexander MacGregor ², Katie Bechman ³, Sanketh Rampes ³ and James Galloway ⁴, ¹Kings College London, London, ²University of East Anglia, Norwich, United Kingdom, ³King's College London, London, United Kingdom, ⁴Kings College London, London, United Kingdom
Background/Purpose: There is high-quality evidence that prompt diagnosis and treatment have beneficial impact on outcomes in RA. Current guidelines from both North America and Europe…
Abstract Number: 199 • 2019 ACR/ARP Annual Meeting
Obesity and Incident Opioid Use in Rheumatoid Arthritis
Joshua Baker¹, Sofia Pedro ² and Kaleb Michaud ³, ¹University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Prevalent chronic use of opioids approximately 17% among patients with rheumatoid arthritis (RA) and has increased over the last decade.(1) Obesity may be a…
Abstract Number: 200 • 2019 ACR/ARP Annual Meeting
A Validated Text-mining Algorithm to Extract Rheumatoid Arthritis Medication Contained in Format-free Fields of Electronic Medical Records
Tjardo Maarseveen¹, Thomas Huizinga ¹, Marcel J.T. Reinders ¹, Erik van den Akker ¹ and Rachel Knevel ¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rapidly expanding collections of Electronic Medical Records (EMR) form a valuable resource for clinical research. Besides entries with a standardized format, EMRs often also…
Abstract Number: 201 • 2019 ACR/ARP Annual Meeting
Identification of Patients with Rheumatoid Arthritis Treated with Biologics Using Standardized Vocabularies
Runsheng Wang¹, Thomas Falconer ² and George Hripcsak ², ¹Columbia University Medical Center, Division of Rheumatology, New York City, ²Columbia University Medical Center, Department of Biomedical Informatics, New York City
Background/Purpose: To improve efficiency and transportability of observational research, common data models have been developed and maintained to translate data from source vocabularies into standardized…
Abstract Number: 202 • 2019 ACR/ARP Annual Meeting
Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies
Cristiano S. Moura ¹, Jeffrey Curtis ², Denis Choquette ³, Gilles Boire ⁴, Vivian P. Bykerk ⁵, Carter Thorne ⁶, Walter P. Maksymowych ⁷, Peter L. Lakatos ⁸, Larry Svenson ⁹, Laura Targownik ¹⁰, Waqqas Afif ⁸ and Sasha Bernatsky¹¹, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵Hospital for Special Surgery, New York, NY, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁸McGill University, Montreal, QC, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Biosimilar use in North America is relatively low, and real-world comparisons of biosimilars and their originator biologics are lacking. We assessed risk factors associated…
Abstract Number: 203 • 2019 ACR/ARP Annual Meeting
Recent Use, Missed Doses and Discontinuation of Infliximab in a Population-Based Cohort: Comparisons of Biosimilar and Originator Exposures
Cristiano S. Moura ¹, Jeffrey Curtis ², Denis Choquette ³, Gilles Boire ⁴, Vivian Bykerk ⁵, Carter Thorne ⁶, Walter P. Maksymowych ⁷, Peter L. Lakatos ⁸, Larry Svenson ⁹, Laura Targownik ¹⁰, Waqqas Afif ⁸ and Sasha Bernatsky¹¹, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵Hospital for Special Surgery, New York City, NY, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada, ⁸McGill University, Montreal, QC, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In North America, biosimilars were approved only relatively recently, and real-world data are few. We described users of infliximab in the US, comparing patient…
Abstract Number: 204 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Magdaliz Gorritz ³, Lawrence Chang ², Jing He ³ and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Plymouth meeting, PA, ⁴Stanford University, Stanford, CA
Background/Purpose: RA patients have an increased risk of malignancy1 and deep-vein thrombosis and pulmonary embolism (DVT/PE)2 and high prevalence of anemia.3 The risks of anemia…
Abstract Number: 205 • 2019 ACR/ARP Annual Meeting
Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis
Bente Glintborg ¹, Rikke Ibsen ², Rebekka Elisabeth Qwist Bilbo ³, Merete Lund Hetland¹ and Jakob Kjellberg ³, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²i2minds, Aarhus, Denmark, ³VIVE, The Danish Centre for Social Science Research, Copenhagen, Denmark
Background/Purpose: Marketing of cheaper biosimilar biological agents has created financial incentives for switching from the corresponding originator drugs (=non-medical switch). The economic benefit might potentially…
Abstract Number: 206 • 2019 ACR/ARP Annual Meeting
Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study
Siegfried Wassenberg¹, Thilo Klopsch ², Anja Plenske ³, Silke Behnck-Knoblau ⁴, Jürgen Jobst ⁴, Pascal Klaus ⁴, Thomas Meng ⁴, Peter-Andreas Löschmann ⁴ and Rolf Rau ⁵, ¹Centre of Rheumatology, Ratingen, Germany, ²Internal Medicine Practice, Neubrandenburg, Germany, ³Pfizer Pharma GmbH, Berlin, Germany, ⁴Pfizer Pharma GmbH, Berlin, Berlin, Germany, ⁵Dusseldorf, Dusseldorf, Germany
Background/Purpose: Clinical trials showed that Etanercept (ETN) is highly effective in reducing clinical disease activity and often leading to remission and radiographic non-progression in patients…
Abstract Number: 207 • 2019 ACR/ARP Annual Meeting
Effects of Successive Switches to Different Biosimilars Infliximab on Immunogenicity in Chronic Inflammatory Diseases in Daily Clinical Practice
Ambre Lauret ¹, Anna Moltó ¹, Vered Abitbol ², Loriane Guterlann ³, Ornella Conort ³, Francois Chast ³, Claire Goulvestre ⁴, Claire Le Jeunne ⁵, Stanislas Chaussade ², Christian Roux ¹, Frédéric Batteux ⁶, Maxime Dougados ⁷, Yannick Allanore ¹ and Jerome Avouac¹, ¹Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ²Paris Descartes University, Cochin Hospital, Gastroenterology department, Paris, France, ³Paris Descartes University, Cochin Hospital, Department of Pharmacy, paris, France, ⁴Paris Descartes University, Cochin Hospital, Immunology Laboratory, Paris, France, ⁵Paris Descartes University, Cochin Hospital, Internal Medicine department, Paris, France, ⁶Paris Descartes University, Cochin Hospital, Immunology Laborator, Paris, France, ⁷Cochin Hospital, Paris, France
Background/Purpose: To determine whether the successive switches from innovator infliximab to a first then a second biosimilar infliximab, or from a first to a second…
Abstract Number: 208 • 2019 ACR/ARP Annual Meeting
Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA)
Patricia Katz¹, Sofia Pedro ² and Kaleb Michaud ³, ¹University of California, San Francisco, san francisco, CA, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Sleep disturbances (SD) are reported to be common in RA but relatively few studies have addressed the issue. We examined the frequency and severity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].